<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="humu24453" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Mutat</journal-id><journal-id journal-id-type="iso-abbrev">Hum Mutat</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1098-1004</journal-id><journal-id journal-id-type="publisher-id">HUMU</journal-id><journal-title-group><journal-title>Human Mutation</journal-title></journal-title-group><issn pub-type="ppub">1059-7794</issn><issn pub-type="epub">1098-1004</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">36030551</article-id><article-id pub-id-type="pmc">9771894</article-id>
<article-id pub-id-type="doi">10.1002/humu.24453</article-id><article-id pub-id-type="publisher-id">HUMU24453</article-id><article-categories><subj-group subj-group-type="overline"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Articles</subject></subj-group></article-categories><title-group><article-title>Biallelic pathogenic variants in <italic toggle="yes">COX11</italic> are associated with an infantile&#x2010;onset mitochondrial encephalopathy</article-title><alt-title alt-title-type="left-running-head">RIUS <sc>et al.</sc>
</alt-title></title-group><contrib-group><contrib id="humu24453-cr-0001" contrib-type="author"><name><surname>Rius</surname><given-names>Rocio</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9871-3126</contrib-id><xref rid="humu24453-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="humu24453-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="humu24453-cr-0002" contrib-type="author"><name><surname>Bennett</surname><given-names>Neal K.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3120-4164</contrib-id><xref rid="humu24453-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="humu24453-cr-0003" contrib-type="author"><name><surname>Bhattacharya</surname><given-names>Kaustuv</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0518-5879</contrib-id><xref rid="humu24453-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="humu24453-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="humu24453-cr-0004" contrib-type="author"><name><surname>Riley</surname><given-names>Lisa G.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1142-316X</contrib-id><xref rid="humu24453-aff-0006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="humu24453-aff-0007" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib id="humu24453-cr-0005" contrib-type="author"><name><surname>Y&#xFC;ksel</surname><given-names>Zafer</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2085-5773</contrib-id><xref rid="humu24453-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="humu24453-cr-0006" contrib-type="author"><name><surname>Formosa</surname><given-names>Luke E.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7740-6151</contrib-id><xref rid="humu24453-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="humu24453-cr-0007" contrib-type="author"><name><surname>Compton</surname><given-names>Alison G.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2725-7055</contrib-id><xref rid="humu24453-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="humu24453-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="humu24453-cr-0008" contrib-type="author"><name><surname>Dale</surname><given-names>Russell C.</given-names></name><xref rid="humu24453-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="humu24453-cr-0009" contrib-type="author"><name><surname>Cowley</surname><given-names>Mark J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9519-5714</contrib-id><xref rid="humu24453-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib><contrib id="humu24453-cr-0010" contrib-type="author"><name><surname>Gayevskiy</surname><given-names>Velimir</given-names></name><xref rid="humu24453-aff-0012" ref-type="aff">
<sup>12</sup>
</xref></contrib><contrib id="humu24453-cr-0011" contrib-type="author"><name><surname>Al Tala</surname><given-names>Saeed M.</given-names></name><xref rid="humu24453-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="humu24453-cr-0012" contrib-type="author"><name><surname>Almehery</surname><given-names>Abdulrahman A.</given-names></name><xref rid="humu24453-aff-0013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib id="humu24453-cr-0013" contrib-type="author"><name><surname>Ryan</surname><given-names>Michael T.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2586-8829</contrib-id><xref rid="humu24453-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="humu24453-cr-0014" contrib-type="author"><name><surname>Thorburn</surname><given-names>David R.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7725-9470</contrib-id><xref rid="humu24453-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="humu24453-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="humu24453-aff-0014" ref-type="aff">
<sup>14</sup>
</xref></contrib><contrib id="humu24453-cr-0015" contrib-type="author"><name><surname>Nakamura</surname><given-names>Ken</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9192-182X</contrib-id><xref rid="humu24453-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="humu24453-aff-0015" ref-type="aff">
<sup>15</sup>
</xref><xref rid="humu24453-aff-0016" ref-type="aff">
<sup>16</sup>
</xref></contrib><contrib id="humu24453-cr-0016" contrib-type="author" corresp="yes"><name><surname>Christodoulou</surname><given-names>John</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8431-0641</contrib-id><xref rid="humu24453-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="humu24453-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="humu24453-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><address><email>john.christodoulou@mcri.edu.au</email></address></contrib></contrib-group><aff id="humu24453-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Brain and Mitochondrial Research Group, Murdoch Children's Research Institute</named-content>
<institution>Royal Children's Hospital</institution>
<city>Melbourne</city>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Paediatrics</named-content>
<institution>University of Melbourne</institution>
<city>Melbourne</city>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Gladstone Institute of Neurological Disease</named-content>
<institution>Gladstone Institutes</institution>
<city>San Francisco</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="humu24453-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Genetic Metabolic Disorders Service</named-content>
<institution>The Children's Hospital at Westmead</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Discipline of Genetic Medicine, Sydney Medical School</named-content>
<institution>University of Sydney</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Specialty of Child &amp; Adolescent Health</named-content>
<institution>University of Sydney</institution>
<city>Sydney</city>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Rare Diseases Functional Genomics</named-content>
<institution>The Children's Hospital at Westmead</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Department of Human Genetics</named-content>
<institution>Bioscientia Healthcare GmbH</institution>
<city>Ingelheim</city>
<country country="DE">Germany</country>
</aff><aff id="humu24453-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute</named-content>
<institution>Monash University</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Department of Paediatric Neurology and Clinical school, The Children's Hospital at Westmead, Faculty of Medicine and Health</named-content>
<institution>University of Sydney</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Children's Cancer Institute &amp; School of Women's and Children's Health</named-content>
<institution>University of New South Wales</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0012">
<label>
<sup>12</sup>
</label>
<named-content content-type="organisation-division">Kinghorn Centre for Clinical Genomics</named-content>
<institution>Garvan Institute of Medical Research</institution>
<city>Sydney</city>
<named-content content-type="country-part">New South Wales</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0013">
<label>
<sup>13</sup>
</label>
<named-content content-type="organisation-division">Pediatric Directorate</named-content>
<institution>Neonatal NICU, Armed Forces Hospital SR</institution>
<city>Khamis Mushayt</city>
<country country="SA">Saudi Arabia</country>
</aff><aff id="humu24453-aff-0014">
<label>
<sup>14</sup>
</label>
<named-content content-type="organisation-division">Victorian Clinical Genetics Services</named-content>
<institution>Royal Children's Hospital</institution>
<city>Melbourne</city>
<named-content content-type="country-part">Victoria</named-content>
<country country="AU">Australia</country>
</aff><aff id="humu24453-aff-0015">
<label>
<sup>15</sup>
</label>
<named-content content-type="organisation-division">Department of Neurology</named-content>
<institution>University of California</institution>
<city>San Francisco</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><aff id="humu24453-aff-0016">
<label>
<sup>16</sup>
</label>
<named-content content-type="organisation-division">Graduate Programs in Biomedical Sciences and Neuroscience</named-content>
<institution>University of California</institution>
<city>San Francisco</city>
<named-content content-type="country-part">California</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold> John Christodoulou, Brain and Mitochondrial Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia.<break/>
Email: <email>john.christodoulou@mcri.edu.au</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>9</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2022</year></pub-date><volume>43</volume><issue seq="260">12</issue><issue-id pub-id-type="doi">10.1002/humu.v43.12</issue-id><fpage>1970</fpage><lpage>1978</lpage><history>
<date date-type="rev-recd"><day>28</day><month>7</month><year>2022</year></date>
<date date-type="received"><day>20</day><month>4</month><year>2022</year></date>
<date date-type="accepted"><day>22</day><month>8</month><year>2022</year></date>
</history><permissions><!--&#x000a9; 2022 Wiley Periodicals LLC.--><copyright-statement content-type="article-copyright">&#xA9; 2022 The Authors. <italic toggle="yes">Human Mutation</italic> published by Wiley Periodicals LLC.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x2010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:HUMU-43-1970.pdf"/><abstract><title>Abstract</title><p>Primary mitochondrial diseases are a group of genetically and clinically heterogeneous disorders resulting from oxidative phosphorylation (OXPHOS) defects. <italic toggle="yes">COX11</italic> encodes a copper chaperone that participates in the assembly of complex IV&#xA0;and has not been previously linked to human disease. In a previous study, we identified that <italic toggle="yes">COX11</italic> knockdown decreased cellular adenosine triphosphate (ATP)&#xA0;derived from respiration, and that ATP levels could be restored with coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) supplementation. This finding is surprising since <italic toggle="yes">COX11</italic> has no known role in CoQ<sub>10</sub> biosynthesis. Here, we report a novel gene&#x2010;disease association by identifying biallelic pathogenic variants in <italic toggle="yes">COX11</italic> associated with infantile&#x2010;onset mitochondrial encephalopathies in two unrelated families using trio genome and exome sequencing. Functional studies showed that mutant COX11 fibroblasts had decreased ATP levels which could be rescued by CoQ<sub>10</sub>. These results not only suggest that <italic toggle="yes">COX11</italic> variants cause defects in energy production but reveal a potential metabolic therapeutic strategy for patients with <italic toggle="yes">COX11</italic> variants.</p></abstract><kwd-group><kwd id="humu24453-kwd-0001">coenzyme Q</kwd><kwd id="humu24453-kwd-0002">COX11</kwd><kwd id="humu24453-kwd-0003">mitochondrial disorders</kwd><kwd id="humu24453-kwd-0004">OXPHOS</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>National Health and Medical Research Council (NHMRC)</funding-source></award-group><award-group id="funding-0002"><funding-source>New South Wales Office of Health and Medical Research Council</funding-source></award-group><award-group id="funding-0003"><funding-source>NIH</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="1"/><page-count count="9"/><word-count count="5603"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2022</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.3.9 mode:remove_FC converted:18.03.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="humu24453-cit-0031">
<string-name>
<surname>Rius</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>, <given-names>N. K.</given-names>
</string-name>, <string-name>
<surname>Bhattacharya</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Riley</surname>, <given-names>L. G.</given-names>
</string-name>, <string-name>
<surname>Y&#xFC;ksel</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Formosa</surname>, <given-names>L. E.</given-names>
</string-name>, <string-name>
<surname>Compton</surname>, <given-names>A. G.</given-names>
</string-name>, <string-name>
<surname>Dale</surname>, <given-names>R. C.</given-names>
</string-name>, <string-name>
<surname>Cowley</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Gayevskiy</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Tala</surname>, <given-names>S. A.</given-names>
</string-name>, <string-name>
<surname>Almehery</surname>, <given-names>A. A.</given-names>
</string-name>, <string-name>
<surname>Ryan</surname>, <given-names>M. T.</given-names>
</string-name>, <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>, <given-names>K.</given-names>
</string-name>, &amp; <string-name>
<surname>Christodoulou</surname>, <given-names>J.</given-names>
</string-name> (<year>2022</year>). <article-title>Biallelic pathogenic variants in <italic toggle="yes">COX11</italic> are associated with an infantile&#x2010;onset mitochondrial encephalopathy</article-title>. <source>Human Mutation</source>, <volume>43</volume>, <fpage>1970</fpage>&#x2013;<lpage>1978</lpage>. <pub-id pub-id-type="doi">10.1002/humu.24453</pub-id>
<pub-id pub-id-type="pmid">36030551</pub-id>
</mixed-citation>
</p><fn-group><fn id="humu24453-note-0001"><p>Rocio Rius and&#xA0;Neal K. Bennett&#xA0;Joint first authors.</p></fn><fn id="humu24453-note-0002"><p>Ken Nakamura and&#xA0;John Christodoulou&#xA0;Joint co&#x2010;last authors.</p></fn></fn-group></notes></front>
  <body>
    <sec id="humu24453-sec-0010">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>Mitochondrial disorders impact more than one in 5000 live births, and often lead to the dysfunction of multiple organ systems and early death. The pathophysiology is believed to result from a primary or secondary disruption in the production of adenosine triphosphate (ATP)&#xA0;by mitochondria, which constitutes the major source of energy that the human body needs (Gorman et al.,&#xA0;<xref rid="humu24453-bib-0011" ref-type="bibr">2016</xref>) (Frazier et al.,&#xA0;<xref rid="humu24453-bib-0007" ref-type="bibr">2019</xref>). ATP is produced in the mitochondria through oxidative phosphorylation (OXPHOS) and involves five protein complexes. Mitochondrial respiratory chain complex IV (cytochrome <italic toggle="yes">c</italic> oxidase; COX; CIV) is composed of 14 subunits encoded by both mitochondrial DNA and nuclear DNA (nDNA) and catalyzes electron transfer from reduced cytochrome <italic toggle="yes">c</italic> to oxygen (O<sub>2</sub>), contributing to the electrochemical transmembrane gradient required to produce ATP (Gorman et al.,&#xA0;<xref rid="humu24453-bib-0011" ref-type="bibr">2016</xref>). Several proteins encoded by the nDNA are required for the proper assembly of CIV, with some previously linked to human mitochondrial disease. For instance, pathogenic variants in <italic toggle="yes">SURF1</italic> are among the most frequent causes of Leigh syndrome (Lake et al.,&#xA0;<xref rid="humu24453-bib-0013" ref-type="bibr">2016</xref>). SURF1 participates in the assembly of CIV as part of the mitochondrial translation regulation assembly intermediate of cytochrome <italic toggle="yes">c</italic> oxidase complex (MITRAC) (Mick et al.,&#xA0;<xref rid="humu24453-bib-0019" ref-type="bibr">2012</xref>). <italic toggle="yes">COX11</italic> (cytochrome <italic toggle="yes">c</italic> oxidase assembly factor 11) has not yet been linked to disease, however, COX11 also participates in COX assembly by mediating copper delivery into to the complex (Bourens &amp; Barrientos,&#xA0;<xref rid="humu24453-bib-0002" ref-type="bibr">2017</xref>). Moreover, knockdown studies using Clustered Regularly Interspaced Short Palindromic Repeats interference (CRISPRi) and a&#xA0;fluorescence resonance energy transfer (FRET)&#x2010;based ATP sensor showed that COX11 is required to maintain mitochondrial&#x2010;derived ATP levels. Supplementation with coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) prevented this decrease in ATP due to COX11 deficiency, even though <italic toggle="yes">COX11</italic> is not known to participate in CoQ<sub>10</sub> synthesis (Mendelsohn et al.,&#xA0;<xref rid="humu24453-bib-0018" ref-type="bibr">2018</xref>). In this study, we describe for the first time two unrelated patients with biallelic <italic toggle="yes">COX11</italic> variants leading to mitochondrial disease and show restoration of ATP levels in one of the patient's cell lines using CoQ<sub>10</sub>.</p>
    </sec>
    <sec sec-type="materials-and-methods" id="humu24453-sec-0020">
      <label>2</label>
      <title>MATERIALS AND METHODS</title>
      <sec id="humu24453-sec-0030">
        <label>2.1</label>
        <title>Ethics and consent</title>
        <p>All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consents were obtained for the clinical genetic testing and the publication of the findings from all patients included in the study. This project was approved by the Human Research Ethics Committee of the Sydney Children's Hospitals Network (ID number 10/CHW/114).</p>
      </sec>
      <sec id="humu24453-sec-0040">
        <label>2.2</label>
        <title>Exome and genome sequencing</title>
        <p>Trio genome sequencing of patient 1 (X1) was performed as previously described (Riley et al.,&#xA0;<xref rid="humu24453-bib-0022" ref-type="bibr">2020</xref>). In brief, samples were sequenced on an Illumina HiSeq X Ten sequencer (v3.0.29.0) to &gt;x30 depth. Reads were aligned to the b37d5 reference genome using Burrows&#x2013;Wheeler alignment (BWA MEM, v0.7.10) (Li &amp; Durbin,&#xA0;<xref rid="humu24453-bib-0016" ref-type="bibr">2009</xref>), sorted using Novosort (v.1.03.01), realigned and recalibrated using GATK (v.3.3). Variants were identified using GATK HaplotypeCaller (v.3.3) (DePristo et al.,&#xA0;<xref rid="humu24453-bib-0004" ref-type="bibr">2011</xref>) and annotated using Variant Effect Predictor (v79). Variant analysis was performed using Seave (Gayevskiy et al.,&#xA0;<xref rid="humu24453-bib-0010" ref-type="bibr">2019</xref>).</p>
        <p>Trio exome sequencing of patient 2 (X2) was performed at the Department of Human Genetics, Bioscientia Healthcare GmbH. The fragmented genomic DNA was enriched using Roche NimbleGen&#xA0;capture technology (SeqCap MedExome Library), amplified and sequenced simultaneously using an Illumina NovaSeq. 6000 system. The target regions were sequenced with an average coverage of 124&#x2010;fold. For about 96% of the areas of interest, a 15&#x2010;fold coverage was obtained. Next &#x2010;generation sequencing data were aligned to the hg19 genome assembly. An in&#x2010;house developed bioinformatics pipeline performed variant calling and annotation.</p>
      </sec>
      <sec id="humu24453-sec-0050">
        <label>2.3</label>
        <title>Blue native Polyacrylamide Gel Electrophoresis&#xA0;(BN&#x2010;PAGE) and immunoblotting</title>
        <p>Blue native Polyacrylamide Gel Electrophoresis(BN&#x2010;PAGE) and immunoblot analysis used 30&#x2009;&#x3BC;g of mitochondria isolated from fibroblasts and solubilized in 1% Digitonin or 1% Triton X&#x2010;100 as previously described (Formosa et al.,&#xA0;<xref rid="humu24453-bib-0006" ref-type="bibr">2020</xref>). Densitometry of BN&#x2010;PAGE data was performed using the ImageLab software (version 5.2.1) on the COX1 signal, and was taken as a ratio to Complex II succinate dehydrogenase complex subunit A. Total protein lysates were extracted from patient X1 fibroblasts for Western blot analysis using total Abcam OXPHOS human WB antibody cocktail (Abcam; ab11041) and Porin/VDAC1 (Abcam; ab14734) as previously published (Lake et al.,&#xA0;<xref rid="humu24453-bib-0014" ref-type="bibr">2017</xref>).</p>
      </sec>
      <sec id="humu24453-sec-0060">
        <label>2.4</label>
        <title>Quantitative polymerase chain reaction&#xA0; (PCR) and complementary DNA sequencing</title>
        <p>Total RNA was isolated from blood of patient X2 using the RNeasy kit (Qiagen). Complementary DNA (cDNA) was amplified with SuperScript III First&#x2010;Strand synthesis kit (Thermo Fisher Scientific) using manufacturer's instructions. Quantitative PCR (qPCR) was conducted using TaqMan Fast Advanced Master Mix (Thermofisher) and TaqMan probes for COX11 (hs01680112) and normalized to HPRT1 (Hs03929096_g1).</p>
        <p>Sequencing of COX11 cDNA (NM_004375.4) was conducted using primers situated in exon 1 and exon 3 (5&#x2032;AGAGGGTTATGGGAGGGCTCTG3&#x2032;, 5&#x2032;AAACGCCAGTGCAGTCTCTC3&#x2032;).</p>
      </sec>
      <sec id="humu24453-sec-0070">
        <label>2.5</label>
        <title>Real&#x2010;time ATP assay</title>
        <p>A FRET&#x2010;based ATP assay was conducted as previously described (Mendelsohn et al.,&#xA0;<xref rid="humu24453-bib-0018" ref-type="bibr">2018</xref>). In brief, patient and control fibroblasts were immortalized using a lenti&#x2010;hTERT&#x2010;Neo Virus following the manufacturer's protocol. A FRET&#x2010;based ATP sensor consisting of Clover and mApple surrounding an ATP&#x2010;sensitive domain was transduced into fibroblasts, which were treated with either 50&#x2009;&#x3BC;M CoQ<sub>10</sub> (ubiquinone # C9538; Sigma) or dimethylformamide&#x2010;vehicle (DMF) control for 5 days. The fibroblasts were then subjected to metabolic perturbations: restricted metabolism to respiration&#x2010;only (phosphate buffered saline, [PBS], with 2% Fetal bovine serum, FBS, 10&#x2009;mM pyruvate and 10&#x2009;mM 2&#x2010;deoxy&#x2010;<sc>d</sc>&#x2010;glucose), ATP depletion (PBS with 2% FBS, 5&#x2009;&#x3BC;M oligomycin and 10&#x2009;mM 2&#x2010;deoxy&#x2010;<sc>d</sc>&#x2010;glucose), or unrestricted basal metabolism (PBS with 2% FBS, 5&#x2009;mM pyruvate and 10&#x2009;mM glucose) for 6&#x2009;h before measuring their ATP level by fluorescence&#x2010;activated cell sorting on a FACS Aria II. FRET was detected by excitation from the 488&#x2010;nm laser, and emission was detected via a 610/20 or 615/30&#x2010;nm filter, on a linear scale.</p>
      </sec>
      <sec id="humu24453-sec-0080">
        <label>2.6</label>
        <title>Platereader luciferase assay for ATP</title>
        <p>Patient and control fibroblasts were immortalized using a lenti&#x2010;hTERT&#x2010;Neo Virus. Fibroblasts were plated into 96&#x2010;well plates, 4000 cells per well, subjected to the above metabolic perturbations for 8&#x2009;h. Following metabolic perturbation, ATP was measured using using CellTiter Glo 2.0 cell viability assay before measuring ATP on a Spectramax M4 platereader. Luminescence was normalized to Hoescht nuclear stain intensity.</p>
      </sec>
      <sec id="humu24453-sec-0090">
        <label>2.7</label>
        <title>MitoSOX&#x2010;based flow cytometric assay</title>
        <p>Control and Patient X1 fibroblasts were cultured with 50&#x2009;&#x3BC;M CoQ10 (ubiquinone; catalog # C9538; Sigma) or DMF vehicle control for 5 days before staining with 2.5&#x2009;&#x3BC;M MitoSOX (Thermo Fisher). for 15&#x2009;min at 37&#xB0;C. Between 4000 and 15,000 cells were sorted per condition. Cells were then incubated in respiration&#x2010;only metabolic substrate for 5&#x2009;h before analysis on a FACS Aria II. Unstained cells were used to set gates, and cells incubated with 2&#x2009;&#x3BC;M rotenone, a complex I inhibitor, were used as positive controls. MitoSOX was detected by excitation from the 488&#x2010;nm laser, and emission was detected via a 610/20 or 615/30&#x2010;nm filter.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="humu24453-sec-0100">
      <label>3</label>
      <title>RESULTS</title>
      <p>Patient X1 (X1) was the first child of consanguineous parents. She presented with congenital sensorineural deafness in the newborn period. She subsequently presented at 6 weeks of age with hypotonia, poor feeding and two clinical events of loss of responsiveness suspected to be seizures. Initial magnetic resonance imaging (MRI) was normal, and phenobarbitone was started. At 3 months of age, she experienced episodes of intermittent respiratory distress and clinical clonic seizures progressed, associated with developmental stasis, visual impairment and poor feeding, necessitating a 2 month admission. Brain MRI showed new lesions in the cerebellar peduncles, cerebrospinal fluid&#xA0;lactate was elevated 2.7&#x2009;mmol/L (N: &lt;2&#x2009;mmol/L), and plasma lactate were intermittently elevated to 5&#x2009;mmol/L. Phenobarbitone, levetiracetam and clobazam appeared to initially stabilize her, although she developed a dyskinetic movement disorder, and a repeat brain MRI at 7 months revealed progressive brain atrophy, dentate nucleus lesions, and diffuse white matter disease (Supporting Information: Figure&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S1</xref>). She required nasogastric feeding and was treated with three antiepileptic drugs. She was also treated with CoQ<sub>10</sub> (in the form of ubiquinone) starting at 25&#x2009;mg twice a day (weight 6&#x2009;kg) from 5 months of age. However, her neurologic symptoms worsened, and her clinical course was complicated by several respiratory infections with respiratory distress, and the patient sadly died at 9 months of age.</p>
      <p>A spectrophotometric assay of OXPHOS enzyme activity was performed as previously described (Frazier et al.,&#xA0;<xref rid="humu24453-bib-0008" ref-type="bibr">2020</xref>). In muscle, all complexes were normal to elevated relative to protein, relative to complex II and relative to citrate synthase (CS). In the liver, complexes I, II and CS were elevated, so when the activities of complexes III and IV were expressed relative to complex II or CS they were borderline low (Table&#xA0;<xref rid="humu24453-tbl-0001" ref-type="table">1</xref>). Enzyme activities of Complex I and IV in fibroblasts were determined using dipstick activity assays (Abcam #ab109720; #ab109876), and showed a mild decrease in CIV (decreased by 40% relative to control A), but no difference in complex I activity (data not shown).</p>
      <table-wrap position="float" id="humu24453-tbl-0001" content-type="Table">
        <label>Table 1</label>
        <caption>
          <p>Spectrophotometric analysis of oxidative phosphorylation (OXPHOS) enzyme activities in muscle and liver from X1</p>
        </caption>
        <table frame="hsides" rules="groups">
          <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
          <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
          <thead valign="bottom">
            <tr valign="bottom">
              <th valign="bottom" rowspan="1" colspan="1"/>
              <th colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Muscle</th>
              <th colspan="3" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Liver</th>
            </tr>
            <tr style="border-bottom:solid 1px #000000" valign="bottom">
              <th valign="bottom" rowspan="1" colspan="1">Enzyme</th>
              <th valign="bottom" rowspan="1" colspan="1">
<p>Residual Activity</p>
<p>(%)</p>
</th>
              <th valign="bottom" rowspan="1" colspan="1">
<p>CS ratio</p>
<p>(%)</p>
</th>
              <th valign="bottom" rowspan="1" colspan="1">
<p>CII ratio</p>
<p>(%)</p>
</th>
              <th valign="bottom" rowspan="1" colspan="1">
<p>Residual Activity</p>
<p>(%)</p>
</th>
              <th valign="bottom" rowspan="1" colspan="1">
<p>CS ratio</p>
<p>(%)</p>
</th>
              <th valign="bottom" rowspan="1" colspan="1">
<p>CII ratio</p>
<p>(%)</p>
</th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td valign="top" rowspan="1" colspan="1">I</td>
              <td valign="top" rowspan="1" colspan="1">
<p>221</p>
<p>(45&#x2212;173)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>182</p>
<p>(70&#x2212;149)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>141</p>
<p>(66&#x2212;147)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>768</p>
<p>(82&#x2212;118)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>218</p>
<p>(77&#x2212;124)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>327</p>
<p>(92&#x2212;121)</p>
</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">II</td>
              <td valign="top" rowspan="1" colspan="1">
<p>160</p>
<p>(58&#x2212;138)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>127</p>
<p>(80&#x2212;109)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">&#x2010;</td>
              <td valign="top" rowspan="1" colspan="1">
<p>236</p>
<p>(88&#x2212;119)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>67</p>
<p>(80&#x2212;126)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">&#x2010;</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">III</td>
              <td valign="top" rowspan="1" colspan="1">
<p>106</p>
<p>(44&#x2212;175)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>81</p>
<p>(30&#x2212;171)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>65</p>
<p>(31&#x2010;161)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>74</p>
<p>(68&#x2010;135)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>21</p>
<p>(61&#x2212;136)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>31</p>
<p>(76&#x2013;125)</p>
</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">IV</td>
              <td valign="top" rowspan="1" colspan="1">
<p>97</p>
<p>(51&#x2212;139)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>78</p>
<p>(77&#x2212;116)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>61</p>
<p>(83&#x2010;126)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>70</p>
<p>(64&#x2212;123)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>20</p>
<p>(68&#x2212;130)</p>
</td>
              <td valign="top" rowspan="1" colspan="1">
<p>29</p>
<p>(65&#x2013;120)</p>
</td>
            </tr>
            <tr>
              <td valign="top" rowspan="1" colspan="1">CS</td>
              <td valign="top" rowspan="1" colspan="1">
<p>125</p>
<p>(66&#x2212;138)</p>
</td>
              <td valign="top" rowspan="1" colspan="1"/>
              <td valign="top" rowspan="1" colspan="1"/>
              <td valign="top" rowspan="1" colspan="1">
<p>346</p>
<p>(94&#x2212;110)</p>
</td>
              <td valign="top" rowspan="1" colspan="1"/>
              <td valign="top" rowspan="1" colspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="humu24453-tbl1-note-0001">
            <p>
<italic toggle="yes">Note</italic>:&#xA0;Activities of OXPHOS enzyme complexes I, II, III, IV and citrate synthase (CS) are expressed as % relative to protein (residual activity), citrate synthase (CS ratio) and CII (CII ratio) of control samples.</p>
          </fn>
        </table-wrap-foot>
        <permissions>
          <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
        </permissions>
      </table-wrap>
      <p>Trio GS identified a homozygous missense variant in <italic toggle="yes">COX11</italic>, NM_004375.4:c.730G&#x2009;&gt;&#x2009;C NP_004366.1:p.(Ala244Pro), with both parents being heterozygous (Supporting Information: Figure&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S3A</xref>). Sanger sequencing in the patient's unaffected siblings showed they were both heterozygous for the variant. The alanine at position 244 has high conservation and is situated within the cytochrome <italic toggle="yes">c</italic> oxidase assembly functional domain. <italic toggle="yes">In silico</italic> software predictions are conflicting (Supporting Information: Table&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S1</xref>) and the variant has not been observed in the gnomAD population database (v3.1.2 accessed October 10, 2021) (Karczewski et al.,&#xA0;<xref rid="humu24453-bib-0012" ref-type="bibr">2020</xref>).</p>
      <p>An unrelated patient (Patient X2) is the first child of consanguineous parents. Antenatal scans revealed severe symmetrical intrauterine growth restriction&#xA0;with absent end&#x2010;diastolic flow. The mother received prenatal dexamethasone, and the delivery was performed via cesarean section due to fetal distress at 34&#x2009;+&#x2009;3rd gestational weeks. Her APGAR scores were 7, 8, 8 at 1, 5 and 10&#x2009;min, respectively. Her weight, length, and head circumference at birth were 970&#x2009;g (&#x2212;6.8 Z&#x2010;score), 36&#x2009;cm (&#x2212;7.0 Z&#x2010;score), and 26.5&#x2009;cm (&#x2212;6.2 Z&#x2010;score), respectively. She had feeding intolerance with abdominal distention suggestive of stage one necrotizing enterocolitis. The initial investigations showed hypoglycemia and increased serum lactate levels ranging from 3 to 6&#x2009;mmol/L (N: 0.5&#x2010;2.2&#x2009;mmol/L) without metabolic acidosis. Other laboratory investigations were unremarkable, including tandem mass spectrometry (MS) and urine gas chromatography&#x2010;MS. The upper gastrointestinal tract barium study showed dysmotility and moderate gastroesophageal reflux disease.</p>
      <p>Electroencephalogram&#xA0;showed generalized epileptiform discharges at 7 months of age, controlled by Levetiracetam. Echocardiography showed an isolated aortopulmonary collateral artery with an insignificant hemodynamic effect. The auditory brainstem response testing showed normal bilateral hearing at a 2&#x2212;4&#x2009;kHz frequency range. At 1 year of age, the brain MRI showed bilateral basal ganglia hyperintensity, mild brain atrophy, and magnetic resonance spectroscopy&#xA0;showed elevated lactate levels in basal ganglia (Supporting Information: Figure&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S2</xref>).</p>
      <p>On her last examination at the age of 3 years, a significant delay in acquiring age&#x2010;appropriate milestones and inattentiveness to surrounding visual and auditory stimuli and occasional focal seizures were noted. She was unable to roll or sit and could not speak any words. She lacked any attempt for vocal communication or a palmar grasp. She had some visual contact, followed her parents, and smiled occasionally. The physical examination revealed microcephaly (43.5&#x2009;cm; &#x2212;3.07 Z&#x2010;score), increased peripheral tone, and brisk deep tendon reflexes. Her weight was 7.67&#x2009;kg (&#x2212;6.89 Z&#x2010;score), her length was 76.5&#x2009;cm (supine; 4.69 Z&#x2010;score), her body mass index was 13.1 (&#x2212;2.8. Z&#x2010;score). Serum lactate level remained elevated with a value of 6.2&#x2009;mmol/L (N: 0.5 to 2.2&#x2009;mmol/L).</p>
      <p>Trio exome sequencing identified a homozygous variant in <italic toggle="yes">COX11</italic> NM_004375.4:c.35_36delinsG NP_004366.1:p.(Val12Glyfs*21), with both parents being heterozygous (Supporting Information: Figure&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S3B</xref>). The subsequent segregation analysis showed that the unaffected younger sister is also heterozygous for the NM_004375.4:c.35_36delinsG NP_004366.1:p.(Val12Glyfs*21) variant. This variant has not been observed in the gnomAD population database (v2.1.1 accessed December 10, 2021) (Karczewski et al.,&#xA0;<xref rid="humu24453-bib-0012" ref-type="bibr">2020</xref>).</p>
      <p>To analyze the effect of the NM_004375.4:c.730G&#x2009;&gt;&#x2009;C NP_004366.1:p.(Ala244Pro) variant in patient X1 on CIV assembly, BN&#x2010;PAGE immunoblot analysis was performed on mitochondria isolated from fibroblasts from proband X1 and age&#x2010;matched controls, solubilized in digitonin (to preserve the supercomplex form) or Triton X100 detergent (to separate the individual OXPHOS complexes into holoenzymes) (Formosa et al.,&#xA0;<xref rid="humu24453-bib-0006" ref-type="bibr">2020</xref>). The results suggested a lower level of assembled monomeric CIV was more evident in the Triton X&#x2010;100 solubilized samples, consistent between COX2, COX4 (Figure&#xA0;<xref rid="humu24453-fig-0001" ref-type="fig">1a</xref>) and COX1 antibodies (Figure&#xA0;<xref rid="humu24453-fig-0001" ref-type="fig">1b</xref>), with normal levels of other OXPHOS subunits in isolated mitochondria compared to controls (Figure&#xA0;<xref rid="humu24453-fig-0001" ref-type="fig">1c</xref>). The modest reduction in CIV levels was consistent with the reduced levels of CIV from analysis of whole cell lysates by sodium dodecyl sulfate (SDS)&#x2010;PAGE western blot with COXII antibody (Figure&#xA0;<xref rid="humu24453-fig-0001" ref-type="fig">1d</xref>).</p>
      <fig position="float" fig-type="Figure" id="humu24453-fig-0001">
        <label>Figure 1</label>
        <caption>
          <p>BN&#x2010;PAGE for complex IV and OXPHOS Western blot in <italic toggle="yes">COX11</italic> fibroblasts. Mitochondria isolated from Patient X1 and control fibroblasts analyzed by BN&#x2010;PAGE immunoblotting for COX2, COX4, (a) and COX1 (b) suggest a decreased level of monomeric CIV more evident in mitochondria solubilized with Triton X&#x2010;100, which separates the individual OXPHOS complexes (marked by *); <sup>&#x2021;</sup>indicates previous COX1 signal and complex II (SDHA) was used as a loading control. (c) The levels of other OXPHOS subunits in isolated mitochondria were similar to controls (CI&#x2010;NDUFA9, CIII&#x2010;CORE1, and&#xA0;CV&#x2010;ATP5A). (d) Representative SDS&#x2010;PAGE and western blot analysis in whole cell lysates with an antibody cocktail targeting individual OXPHOS complex subunits showed consistently lower levels of CIV in patient X1; porin (VDAC1) was used as a loading control. BN, Blue native;&#xA0;CIV,&#xA0;complex IV; OXPHOS, oxidative phosphorylation; BN&#x2010;&#xA0;PAGE, Blue native polyacrylamide gel electrophoresis;&#xA0;SDHA,&#xA0;succinate dehydrogenase complex subunit A; SDS, sodium dodecyl sulfate.</p>
        </caption>
        <graphic xlink:href="HUMU-43-1970-g001" position="anchor" id="jats-graphic-1"/>
      </fig>
      <p>To assess if the NM_004375.4:c.730G&#x2009;&gt;&#x2009;C NP_004366.1:p.(Ala244Pro) homozygous variant identified in patient X1 could impact ATP levels, we assayed steady&#x2010;state ATP levels with different substrates and plus or minus CoQ<sub>10</sub> supplementation using patient X1 fibroblasts.</p>
      <p>Under basal conditions, where glycolysis and respiration are unrestricted, ATP levels were comparable between patient X1 and control cells derived from a healthy individual, in the presence or absence of 50&#x2009;&#xB5;M CoQ<sub>10</sub>. However, when glycolytic ATP generation was blocked with 2&#x2010;deoxy&#x2010;<sc>d</sc>&#x2010;glucose, the patient X1 (<italic toggle="yes">COX11</italic>) fibroblasts showed markedly decreased ATP levels compared with control cells (Figure&#xA0;<xref rid="humu24453-fig-0002" ref-type="fig">2</xref>). In the presence of 50&#x2009;&#xB5;M CoQ<sub>10</sub>, patient X1 (<italic toggle="yes">COX11</italic>) cells showed substantial restoration of ATP levels, while control cells showed no significant change (Figure&#xA0;<xref rid="humu24453-fig-0002" ref-type="fig">2</xref>).</p>
      <fig position="float" fig-type="Figure" id="humu24453-fig-0002">
        <label>Figure 2</label>
        <caption>
          <p>COX11 variation is associated with decreased respiration&#x2010;derived ATP&#xA0;levels, which can be restored with CoQ<sub>10.</sub> ATP levels were measured by flow cytometry after 6&#x2009;h of metabolic substrate in patient X1 (<italic toggle="yes">COX11</italic>) and control fibroblasts expressing a genetically encoded FRET&#x2010;based ATP sensor. Basal ATP levels were similar between all conditions. Respiration&#x2010;only ATP levels were normalized within each cell line to basal and depleted conditions. Patient XI (<italic toggle="yes">COX11</italic>) and control fibroblast ATP levels remained high with unrestricted basal metabolism. When metabolism was restricted to respiration&#x2010;only by addition of 10 mM 2&#x2010;deoxy&#x2010;<sc>d</sc>&#x2010;glucose, ATP levels dropped in patient cells that were treated with the vehicle, while patient XI (<italic toggle="yes">COX11</italic>) cells maintained higher levels of ATP with CoQ<sub>10</sub> treatment. Data show mean &#xB1; SEM; <italic toggle="yes">n</italic>=&#x2009;2&#x2212;8 replicates of at least 300 cells per condition, compiled from two independent experiments. ***<italic toggle="yes">p</italic>&lt;&#x2009;0.001, *&lt;0.05 by two&#x2010;way analysis of variance with Tukey's multiple comparisons test. ATP adenosine triphosphate;&#xA0;FRET,&#xA0;fluorescence resonance energy transfer.</p>
        </caption>
        <graphic xlink:href="HUMU-43-1970-g002" position="anchor" id="jats-graphic-3"/>
      </fig>
      <p>These data suggest that the patient X1 (<italic toggle="yes">COX11</italic>) cells show a very similar functional defect to <italic toggle="yes">COX11</italic> knock&#x2010;down cells in having inadequate ATP generation that can be rescued by CoQ<sub>10</sub> (Mendelsohn et al.,&#xA0;<xref rid="humu24453-bib-0018" ref-type="bibr">2018</xref>).</p>
      <p>To corroborate the results using a different method, ATP content was also measured using luciferase assay for ATP (Supporting Information: Figure&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S4</xref>), showing a similar decrease in respiration&#x2010;derived ATP levels in <italic toggle="yes">COX11</italic> patient cells, which was rescued by CoQ<sub>10</sub> supplementation.</p>
      <p>RNA was extracted from total peripheral blood of patient X2 and reverse&#x2010;transcribed. qPCR&#xA0;was performed using TaqMan gene expression assays, showing no significant difference in <italic toggle="yes">COX11</italic> transcript expression compared to controls (Supporting Information: Figure&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S5A</xref>). In addition, cDNA sequencing identified the homozygous NM_004375.4:c.35_36delinsG variant in the transcript (Supporting Information: Figure&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S5B</xref>). Together, these data suggest that the mutant transcript is not degraded by nonsense mediated decay and is therefore predicted to cause a truncated protein. Unfortunately, no tissue samples or cultured fibroblasts were available for further studies.</p>
    </sec>
    <sec sec-type="discussion" id="humu24453-sec-0110">
      <label>4</label>
      <title>DISCUSSION</title>
      <p>While COX11 is known to play an important role in the assembly of CIV by mediating copper delivery into the COX1 Cu<sub>B</sub> center (Bourens &amp; Barrientos,&#xA0;<xref rid="humu24453-bib-0002" ref-type="bibr">2017</xref>), disease&#x2010;causing variants in <italic toggle="yes">COX11</italic> have not previously been reported. We identify two such individuals with mitochondrial encephalopathies that overlap the Leigh Syndrome spectrum (Lake et al.,&#xA0;<xref rid="humu24453-bib-0013" ref-type="bibr">2016</xref>) and show that one of these variants causes a decrease in respiration&#x2010;derived ATP levels. CIV couples electron transfer to oxygen, resulting in the production of water and the pumping of protons across the mitochondrial inner membrane. Therefore, defects in CIV could lead to a decrease in mitochondrial membrane potential or protonmotive force that powers respiration&#x2010;derived ATP production. Cofactor therapies such as CoQ<sub>10</sub> have been used to treat disorders in biosynthesis of CoQ<sub>10</sub>, and a synthetic analogue of CoQ<sub>10</sub> (Idebenone) is licensed for the treatment in patients with Leber Hereditary Optic Neuropathy&#xA0;(Lyseng&#x2010;Williamson,&#xA0;<xref rid="humu24453-bib-0017" ref-type="bibr">2016</xref>). However, there is very limited evidence on the effectiveness of CoQ<sub>10</sub> for patients with other mitochondrial diseases, especially in the pediatric population (Neergheen et al.,&#xA0;<xref rid="humu24453-bib-0020" ref-type="bibr">2017</xref>). We observed that the decline in ATP levels in <italic toggle="yes">COX11</italic> patient fibroblasts was ameliorated with CoQ<sub>10</sub> supplementation.</p>
      <p>Since COX11 has no known role in CoQ<sub>10</sub> biosynthesis, it is unclear why CoQ<sub>10</sub> supplementation would address functional deficits in cells with <italic toggle="yes">COX11</italic> variants. We previously showed that CRISPRi knockdown of <italic toggle="yes">COX11</italic> in human K562 cells does not significantly change total amounts of CoQ<sub>10</sub>, suggesting that <italic toggle="yes">COX11</italic> loss of function may not create a deficit in CoQ<sub>10</sub> (Mendelsohn et al.,&#xA0;<xref rid="humu24453-bib-0018" ref-type="bibr">2018</xref>). Here, we observe that patient X1 expressing a <italic toggle="yes">COX11</italic> variant, has lower CIV levels in fibroblasts. Therefore, CoQ<sub>10</sub> supplementation may restore ATP levels by restoring electron transport chain complex levels, for instance by promoting complex assembly, by preventing complex degradation, or by promoting mitochondrial biogenesis (Santos&#x2010;Ocana et al.,&#xA0;<xref rid="humu24453-bib-0024" ref-type="bibr">2002</xref>). Alternatively, CoQ<sub>10</sub> supplementation could increase ATP levels by directly contributing electrons to complex III, however, our previously published results show that CoQ<sub>10</sub> supplementation increased the fraction of oxidized versus reduced state (Mendelsohn et al.,&#xA0;<xref rid="humu24453-bib-0018" ref-type="bibr">2018</xref>). CoQ<sub>10</sub> levels may also regulate enzyme activity within the electron transport chain, or levels of supercomplex, each of which are believed to regulate ATP production (Acin&#x2010;Perez et al.,&#xA0;<xref rid="humu24453-bib-0001" ref-type="bibr">2008</xref>; Salviati et al.,&#xA0;<xref rid="humu24453-bib-0023" ref-type="bibr">2005</xref>) (Lapuente&#x2010;Brun et al.,&#xA0;<xref rid="humu24453-bib-0015" ref-type="bibr">2013</xref>).</p>
      <p>While we demonstrate that cells from a patient with <italic toggle="yes">COX11</italic> variants have decreased respiration&#x2010;derived ATP, it is possible that disruptions of other non&#x2010;energetic functions of CIV or the electron transport chain also contribute to the disease pathophysiology. While there are no known sites of reactive oxygen species generation in CIV, it is possible that decreasing levels of CIV increase reactive oxygen species generation from other upstream sites in the electron transport chain (Quinlan et al.,&#xA0;<xref rid="humu24453-bib-0021" ref-type="bibr">2013</xref>). Furthermore, COX11 also acts as a copper chaperone, and facilitates the formation of copper centers in CIV. Knockdown or mutation in <italic toggle="yes">COX11</italic> may result in disrupted copper mobilization. Free copper in the cytosol can contribute to the conversion of hydrogen peroxide to damaging hydroxyl radicals (Collin,&#xA0;<xref rid="humu24453-bib-0003" ref-type="bibr">2019</xref>). Since CoQ<sub>10</sub> can accept electrons and in some contexts has been considered an antioxidant, it is possible that CoQ<sub>10</sub> supplementation may also address excessive ROS generation resulting from decreasing levels of CIV. However, mitochondrial superoxide was not significantly altered with CoQ<sub>10</sub> treatment in patient X1 fibroblasts (Supporting Information: Figure&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S6</xref>).</p>
      <p>The ability of CoQ<sub>10</sub> to restore ATP raises questions about its therapeutic potential for patients with <italic toggle="yes">COX11</italic> variants. Although patient X1 declined despite CoQ<sub>10</sub> supplementation later in her disease, our data suggest boosting CoQ<sub>10</sub> may be a promising therapeutic strategy for COX11 deficiency. Therapeutic doses of CoQ<sub>10</sub> supplementation in patients with CoQ<sub>10</sub> deficiency range from 5 to 50 mg/kg/day (Desbats et al.,&#xA0;<xref rid="humu24453-bib-0005" ref-type="bibr">2015</xref>). Patient X1 received low dose CoQ<sub>10</sub> (8&#x2009;mg/kg/day), and it was administered late in the course of her disease. Therefore, we speculate that efficacy will require earlier intervention, higher doses and improved bioavailability in vulnerable tissues including the brain. CoQ<sub>10</sub> is highly hydrophobic (Suarez&#x2010;Rivero et al.,&#xA0;<xref rid="humu24453-bib-0026" ref-type="bibr">2021</xref>), and higher doses may be needed for COX11 deficiency. Notably, the efficacy of CoQ<sub>10</sub> therapy may also depend on whether toxicity ultimately results from insufficient energy, which also remains to be proven.</p>
      <p>The modified mitochondrial disease criteria&#xA0;score suggests a probable mitochondrial disorder for patient X2, although functional studies could not be performed (Witters et al.,&#xA0;<xref rid="humu24453-bib-0030" ref-type="bibr">2018</xref>). When it is considered together with a biallelic truncating variant in <italic toggle="yes">COX11</italic>, it seems likely that the p.(Val12Glyfs*21) variant abolishes import of the protein into mitochondria as suggested by mitochondrial localization <italic toggle="yes">in silico</italic> prediction tools MitoFates (Fukasawa et al.,&#xA0;<xref rid="humu24453-bib-0009" ref-type="bibr">2015</xref>), and Tppred 3.0 (Savojardo et al.,&#xA0;<xref rid="humu24453-bib-0025" ref-type="bibr">2015</xref>) (Supporting Information: Table&#xA0;<xref rid="humu24453-suppl-0001" ref-type="supplementary-material">S2&amp;S3</xref>).</p>
      <p>While rare, variants affecting the mitochondrial targeting sequence have been described before in other genes causing mitochondrial disease such as <italic toggle="yes">MLYCD</italic>, <italic toggle="yes">PDHA1</italic> and <italic toggle="yes">ISCA1</italic>, leading to defects such as reduced mitochondrial protein import or protein mistargeting (Takakubo et al.,&#xA0;<xref rid="humu24453-bib-0027" ref-type="bibr">1995</xref>; Torraco et al.,&#xA0;<xref rid="humu24453-bib-0028" ref-type="bibr">2018</xref>; Wightman et al.,&#xA0;<xref rid="humu24453-bib-0029" ref-type="bibr">2003</xref>). However, a cell line of patient X2 was not available and validation studies were not performed.</p>
      <p>In summary, our study demonstrates that biallelic pathogenic variants in <italic toggle="yes">COX11</italic> are a causative of mitochondrial encephalopathy. Further research including the interaction of CoQ<sub>10</sub> supplementation in patients with COX11&#x2010;related mitochondrial disease could be of interest to elucidate potential treatment targets.</p>
    </sec>
    <sec sec-type="COI-statement" id="humu24453-sec-0130">
      <title>CONFLICT OF INTEREST</title>
      <p>The authors declare no conflict of interest.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material id="humu24453-suppl-0001" position="float" content-type="local-data">
        <caption>
          <p>Supporting information.</p>
        </caption>
        <media xlink:href="HUMU-43-1970-s001.pdf"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="humu24453-sec-0120">
      <title>ACKNOWLEDGMENTS</title>
      <p>The Chair in Genomic Medicine awarded to J. C. is generously supported by The Royal Children's Hospital Foundation. We are grateful to the Crane, Perkins and Miller families for their generous financial support. We thank the Kinghorn Center for Clinical Genomics for assistance with production and processing of genome sequencing data. L. E. F. acknowledges support from the Mito Foundation. M. J. C. acknowledges support from the Luminesce Alliance. We thank Dr. Michio Hirano for providing fibroblasts from healthy individuals for controls.&#xA0;K. N. and N. K. B. were supported by NIH R01AG065428 to K. N. N. K. B. was also supported by NIH award F32 AG063457&#x2010;01, and a Berkelhammer Award for Excellence in Neuroscience. This researchstudy was supported by a New South Wales Office of Health and Medical Research Council Sydney Genomics Collaborative grant (J. C.). We acknowledge funding from the National Health and Medical Research Council (NHMRC): Project Grants GNT1165217 (M. T. R.) and GNT1164479 (D. R. T.), Principal Research Fellowship GNT1155244 (D. R. T.), and Investigator Grant 2010149 to L. E. F. The research conducted at the Murdoch Children's Research Institute was supported by the Victorian Government's Operational Infrastructure Support Program.&#xA0;Open access publishing facilitated by The University of Melbourne, as part of the Wiley &#x2010; The University of Melbourne agreement via the Council of Australian University Librarians.</p>
    </ack>
    <ref-list content-type="cited-references" id="humu24453-bibl-0001">
      <title>REFERENCES</title>
      <ref id="humu24453-bib-0001">
        <mixed-citation publication-type="journal" id="humu24453-cit-0001">
<string-name>
<surname>Acin&#x2010;Perez</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x2010;Silva</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Peleato</surname>, <given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Perez&#x2010;Martos</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Enriquez</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2008</year>, November 21). <article-title>Respiratory active mitochondrial supercomplexes</article-title>. <source>Molecular Cell</source>, <volume>32</volume>(<issue>4</issue>), <fpage>529</fpage>&#x2013;<lpage>539</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2008.10.021</pub-id>
<pub-id pub-id-type="pmid">19026783</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0002">
        <mixed-citation publication-type="journal" id="humu24453-cit-0002">
<string-name>
<surname>Bourens</surname>, <given-names>M.</given-names>
</string-name>&#xA0;&amp; <string-name>
<surname>Barrientos</surname>, <given-names>A.</given-names>
</string-name> (<year>2017</year>, March). <article-title>A CMC1&#x2010;knockout reveals translation&#x2010;independent control of human mitochondrial complex IV biogenesis</article-title>. <source>EMBO Reports</source>, <volume>18</volume>(<issue>3</issue>), <fpage>477</fpage>&#x2013;<lpage>494</lpage>. <pub-id pub-id-type="doi">10.15252/embr.201643103</pub-id>
<pub-id pub-id-type="pmid">28082314</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0003">
        <mixed-citation publication-type="journal" id="humu24453-cit-0003">
<string-name>
<surname>Collin</surname>, <given-names>F.</given-names>
</string-name> (<year>2019</year>, May 15). <article-title>Chemical basis of reactive oxygen species reactivity and involvement in neurodegenerative diseases</article-title>. <source>International Journal of Molecular Sciences</source>, <volume>20</volume>(<issue>10</issue>), <elocation-id>2407</elocation-id>. <pub-id pub-id-type="doi">10.3390/ijms20102407</pub-id>
<pub-id pub-id-type="pmid">31096608</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0004">
        <mixed-citation publication-type="journal" id="humu24453-cit-0004">
<string-name>
<surname>DePristo</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Banks</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Poplin</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Garimella</surname>, <given-names>K. V.</given-names>
</string-name>, <string-name>
<surname>Maguire</surname>, <given-names>J. R.</given-names>
</string-name>, <string-name>
<surname>Hartl</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Philippakis</surname>, <given-names>A. A.</given-names>
</string-name>, <string-name>
<surname>del Angel</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Rivas</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Hanna</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>McKenna</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Fennell</surname>, <given-names>T. J.</given-names>
</string-name>, <string-name>
<surname>Kernytsky</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>Sivachenko</surname>, <given-names>A. Y.</given-names>
</string-name>, <string-name>
<surname>Cibulskis</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Gabriel</surname>, <given-names>S. B.</given-names>
</string-name>, <string-name>
<surname>Altshuler</surname>, <given-names>D.</given-names>
</string-name>, &amp; <string-name>
<surname>Daly</surname>, <given-names>M. J.</given-names>
</string-name> (<year>2011</year>, May). <article-title>A framework for variation discovery and genotyping using next&#x2010;generation DNA sequencing data</article-title>. <source>Nature Genetics</source>, <volume>43</volume>(<issue>5</issue>), <fpage>491</fpage>&#x2013;<lpage>498</lpage>. <pub-id pub-id-type="doi">10.1038/ng.806</pub-id>
<pub-id pub-id-type="pmid">21478889</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0005">
        <mixed-citation publication-type="journal" id="humu24453-cit-0005">
<string-name>
<surname>Desbats</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Lunardi</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Doimo</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Trevisson</surname>, <given-names>E.</given-names>
</string-name>, &amp; <string-name>
<surname>Salviati</surname>, <given-names>L.</given-names>
</string-name> (<year>2015</year>, January). <article-title>Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency</article-title>. <source>Journal of Inherited Metabolic Disease</source>, <volume>38</volume>(<issue>1</issue>), <fpage>145</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1007/s10545-014-9749-9</pub-id>
<pub-id pub-id-type="pmid">25091424</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0006">
        <mixed-citation publication-type="journal" id="humu24453-cit-0006">
<string-name>
<surname>Formosa</surname>, <given-names>L. E.</given-names>
</string-name>, <string-name>
<surname>Muellner&#x2010;Wong</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Reljic</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Sharpe</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Jackson</surname>, <given-names>T. D.</given-names>
</string-name>, <string-name>
<surname>Beilharz</surname>, <given-names>T. H.</given-names>
</string-name>, <string-name>
<surname>Stojanovski</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Lazarou</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Stroud</surname>, <given-names>D. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Ryan</surname>, <given-names>M. T.</given-names>
</string-name> (<year>2020</year>, Apr 21). <article-title>Dissecting the roles of mitochondrial complex I intermediate assembly complex factors in the biogenesis of complex I</article-title>. <source>Cell Reports</source>, <volume>31</volume>(<issue>3</issue>), <elocation-id>107541</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.celrep.2020.107541</pub-id>
<pub-id pub-id-type="pmid">32320651</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0007">
        <mixed-citation publication-type="journal" id="humu24453-cit-0007">
<string-name>
<surname>Frazier</surname>, <given-names>A. E.</given-names>
</string-name>, <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name>, &amp; <string-name>
<surname>Compton</surname>, <given-names>A. G.</given-names>
</string-name> (<year>2019</year>, April 5). <article-title>Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology</article-title>. <source>Journal of Biological Chemistry</source>, <volume>294</volume>(<issue>14</issue>), <fpage>5386</fpage>&#x2013;<lpage>5395</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R117.809194</pub-id>
<pub-id pub-id-type="pmid">29233888</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0008">
        <mixed-citation publication-type="journal" id="humu24453-cit-0008">
<string-name>
<surname>Frazier</surname>, <given-names>A. E.</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>, <given-names>A. E.</given-names>
</string-name>, <string-name>
<surname>Turnbull</surname>, <given-names>D. M.</given-names>
</string-name>, <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name>, &amp; <string-name>
<surname>Taylor</surname>, <given-names>R. W.</given-names>
</string-name> (<year>2020</year>). <article-title>Assessment of mitochondrial respiratory chain enzymes in cells and tissues</article-title>. <source>Methods in Cell Biology</source>, <volume>155</volume>, <fpage>121</fpage>&#x2013;<lpage>156</lpage>. <pub-id pub-id-type="doi">10.1016/bs.mcb.2019.11.007</pub-id>
<pub-id pub-id-type="pmid">32183956</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0009">
        <mixed-citation publication-type="journal" id="humu24453-cit-0009">
<string-name>
<surname>Fukasawa</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Tsuji</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Fu</surname>, <given-names>S. C.</given-names>
</string-name>, <string-name>
<surname>Tomii</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Horton</surname>, <given-names>P.</given-names>
</string-name>, &amp; <string-name>
<surname>Imai</surname>, <given-names>K.</given-names>
</string-name> (<year>2015</year>, April). <article-title>MitoFates: improved prediction of mitochondrial targeting sequences and their cleavage sites</article-title>. <source>Molecular &amp; Cellular Proteomics</source>, <volume>14</volume>(<issue>4</issue>), <fpage>1113</fpage>&#x2013;<lpage>1126</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M114.043083</pub-id>
<pub-id pub-id-type="pmid">25670805</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0010">
        <mixed-citation publication-type="journal" id="humu24453-cit-0010">
<string-name>
<surname>Gayevskiy</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Roscioli</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Dinger</surname>, <given-names>M. E.</given-names>
</string-name>, &amp; <string-name>
<surname>Cowley</surname>, <given-names>M. J.</given-names>
</string-name> (<year>2019</year>, Jan 1). <article-title>Seave: a comprehensive web platform for storing and interrogating human genomic variation</article-title>. <source>Bioinformatics</source>, <volume>35</volume>(<issue>1</issue>), <fpage>122</fpage>&#x2013;<lpage>125</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/bty540</pub-id>
<pub-id pub-id-type="pmid">30561546</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0011">
        <mixed-citation publication-type="journal" id="humu24453-cit-0011">
<string-name>
<surname>Gorman</surname>, <given-names>G. S.</given-names>
</string-name>, <string-name>
<surname>Chinnery</surname>, <given-names>P. F.</given-names>
</string-name>, <string-name>
<surname>DiMauro</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hirano</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Koga</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>McFarland</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Suomalainen</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name>, <string-name>
<surname>Zeviani</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Turnbull</surname>, <given-names>D. M.</given-names>
</string-name> (<year>2016</year>, Oct 20). <article-title>Mitochondrial diseases</article-title>. <source>Nature Reviews Disease Primers</source>, <volume>2</volume>, <elocation-id>16080</elocation-id>. <pub-id pub-id-type="doi">10.1038/nrdp.2016.80</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0012">
        <mixed-citation publication-type="journal" id="humu24453-cit-0012">
<string-name>
<surname>Karczewski</surname>, <given-names>K. J.</given-names>
</string-name>, <string-name>
<surname>Francioli</surname>, <given-names>L. C.</given-names>
</string-name>, <string-name>
<surname>Tiao</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Cummings</surname>, <given-names>B. B.</given-names>
</string-name>, <string-name>
<surname>Alfoldi</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Collins</surname>, <given-names>R. L.</given-names>
</string-name>, <string-name>
<surname>Laricchia</surname>, <given-names>K. M.</given-names>
</string-name>, <string-name>
<surname>Ganna</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Birnbaum</surname>, <given-names>D. P.</given-names>
</string-name>, <string-name>
<surname>Gauthier</surname>, <given-names>L. D.</given-names>
</string-name>, <string-name>
<surname>Brand</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Solomonson</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Watts</surname>, <given-names>N. A.</given-names>
</string-name>, <string-name>
<surname>Rhodes</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Singer&#x2010;Berk</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>England</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Seaby</surname>, <given-names>E. G.</given-names>
</string-name>, <string-name>
<surname>Kosmicki</surname>, <given-names>J. A.</given-names>
</string-name>, &#x2026; <string-name>
<surname>MacArthur</surname>, <given-names>D. G.</given-names>
</string-name> (<year>2020</year>, May). <article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title>. <source>Nature</source>, <volume>581</volume>(<issue>7809</issue>), <fpage>434</fpage>&#x2013;<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id>
<pub-id pub-id-type="pmid">32461654</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0013">
        <mixed-citation publication-type="journal" id="humu24453-cit-0013">
<string-name>
<surname>Lake</surname>, <given-names>N. J.</given-names>
</string-name>, <string-name>
<surname>Compton</surname>, <given-names>A. G.</given-names>
</string-name>, <string-name>
<surname>Rahman</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name> (<year>2016</year>, February). <article-title>Leigh syndrome: One disorder, more than 75 monogenic causes</article-title>. <source>Annals of Neurology</source>, <volume>79</volume>(<issue>2</issue>), <fpage>190</fpage>&#x2013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24551</pub-id>
<pub-id pub-id-type="pmid">26506407</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0014">
        <mixed-citation publication-type="journal" id="humu24453-cit-0014">
<string-name>
<surname>Lake</surname>, <given-names>N. J.</given-names>
</string-name>, <string-name>
<surname>Webb</surname>, <given-names>B. D.</given-names>
</string-name>, <string-name>
<surname>Stroud</surname>, <given-names>D. A.</given-names>
</string-name>, <string-name>
<surname>Richman</surname>, <given-names>T. R.</given-names>
</string-name>, <string-name>
<surname>Ruzzenente</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Compton</surname>, <given-names>A. G.</given-names>
</string-name>, <string-name>
<surname>Mountford</surname>, <given-names>H. S.</given-names>
</string-name>, <string-name>
<surname>Pulman</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zangarelli</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Rio</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Bodaert</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Assouline</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Sherpa</surname>, <given-names>M. D.</given-names>
</string-name>, <string-name>
<surname>Schadt</surname>, <given-names>E. E.</given-names>
</string-name>, <string-name>
<surname>Houten</surname>, <given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Byrnes</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>McCormick</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Zolkipli&#x2010;Cunningham</surname>, <given-names>Z.</given-names>
</string-name>, <string-name>
<surname>Haude</surname>, <given-names>K.</given-names>
</string-name>, &#x2026; <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name> (<year>2017</year>, August 3). <article-title>Biallelic mutations in MRPS34 lead to instability of the small mitoribosomal subunit and leigh syndrome</article-title>. <source>American Journal of Human Genetics</source>, <volume>101</volume>(<issue>2</issue>), <fpage>239</fpage>&#x2013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2017.07.005</pub-id>
<pub-id pub-id-type="pmid">28777931</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0015">
        <mixed-citation publication-type="journal" id="humu24453-cit-0015">
<string-name>
<surname>Lapuente&#x2010;Brun</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Moreno&#x2010;Loshuertos</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Acin&#x2010;Perez</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Latorre&#x2010;Pellicer</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Colas</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Balsa</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Perales&#x2010;Clemente</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Quiros</surname>, <given-names>P. M.</given-names>
</string-name>, <string-name>
<surname>Calvo</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Rodriguez&#x2010;Hernandez</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Navas</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Cruz</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Carracedo</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Lopez&#x2010;Otin</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Perez&#x2010;Martos</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x2010;Silva</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x2010;Vizarra</surname>, <given-names>E.</given-names>
</string-name>, &amp; <string-name>
<surname>Enriquez</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2013</year>, Junuary 28). <article-title>Supercomplex assembly determines electron flux in the mitochondrial electron transport chain</article-title>. <source>Science</source>, <volume>340</volume>(<issue>6140</issue>), <fpage>1567</fpage>&#x2013;<lpage>1570</lpage>. <pub-id pub-id-type="doi">10.1126/science.1230381</pub-id>
<pub-id pub-id-type="pmid">23812712</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0016">
        <mixed-citation publication-type="journal" id="humu24453-cit-0016">
<string-name>
<surname>Li</surname>, <given-names>H.</given-names>
</string-name>&#xA0;&amp; <string-name>
<surname>Durbin</surname>, <given-names>R.</given-names>
</string-name> (<year>2009</year>, July 15). <article-title>Fast and accurate short read alignment with Burrows&#x2010;Wheeler transform</article-title>. <source>Bioinformatics</source>, <volume>25</volume>(<issue>14</issue>), <fpage>1754</fpage>&#x2013;<lpage>1760</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp324</pub-id>
<pub-id pub-id-type="pmid">19451168</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0017">
        <mixed-citation publication-type="journal" id="humu24453-cit-0017">
<string-name>
<surname>Lyseng&#x2010;Williamson</surname>, <given-names>K. A.</given-names>
</string-name> (<year>2016</year>). <article-title>May). idebenone: A review in leber's hereditary optic neuropathy</article-title>. <source>Drugs</source>, <volume>76</volume>(<issue>7</issue>), <fpage>805</fpage>&#x2013;<lpage>813</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-016-0574-3</pub-id>
<pub-id pub-id-type="pmid">27071925</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0018">
        <mixed-citation publication-type="journal" id="humu24453-cit-0018">
<string-name>
<surname>Mendelsohn</surname>, <given-names>B. A.</given-names>
</string-name>, <string-name>
<surname>Bennett</surname>, <given-names>N. K.</given-names>
</string-name>, <string-name>
<surname>Darch</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>, <given-names>M. K.</given-names>
</string-name>, <string-name>
<surname>Pucciarelli</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Horlbeck</surname>, <given-names>M. A.</given-names>
</string-name>, <string-name>
<surname>Gilbert</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Hyun</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Kampmann</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Nakamura</surname>, <given-names>J. L.</given-names>
</string-name>, &amp; <string-name>
<surname>Nakamura</surname>, <given-names>K.</given-names>
</string-name> (<year>2018</year>, August). <article-title>A high&#x2010;throughput screen of real&#x2010;time ATP levels in individual cells reveals mechanisms of energy failure</article-title>. <source>PLoS Biology</source>, <volume>16</volume>(<issue>8</issue>), <elocation-id>e2004624</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pbio.2004624</pub-id>
<pub-id pub-id-type="pmid">30148842</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0019">
        <mixed-citation publication-type="journal" id="humu24453-cit-0019">
<string-name>
<surname>Mick</surname>, <given-names>D. U.</given-names>
</string-name>, <string-name>
<surname>Dennerlein</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Wiese</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Reinhold</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Pacheu&#x2010;Grau</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Lorenzi</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Sasarman</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Weraarpachai</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Shoubridge</surname>, <given-names>E. A.</given-names>
</string-name>, <string-name>
<surname>Warscheid</surname>, <given-names>B.</given-names>
</string-name>, &amp; <string-name>
<surname>Rehling</surname>, <given-names>P.</given-names>
</string-name> (<year>2012</year>, December 21). <article-title>MITRAC links mitochondrial protein translocation to respiratory&#x2010;chain assembly and translational regulation</article-title>. <source>Cell</source>, <volume>151</volume>(<issue>7</issue>), <fpage>1528</fpage>&#x2013;<lpage>1541</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.11.053</pub-id>
<pub-id pub-id-type="pmid">23260140</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0020">
        <mixed-citation publication-type="journal" id="humu24453-cit-0020">
<string-name>
<surname>Neergheen</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Chalasani</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Wainwright</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Yubero</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Montero</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Artuch</surname>, <given-names>R.</given-names>
</string-name>, &amp; <string-name>
<surname>Hargreaves</surname>, <given-names>I.</given-names>
</string-name> (<year>2017</year>). <article-title>Coenzyme Q10 in the treatment of mitochondrial disease</article-title>. <source>Journal of Inborn Errors of Metabolism and Screening</source>, <volume>5</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/2326409817707771</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0021">
        <mixed-citation publication-type="journal" id="humu24453-cit-0021">
<string-name>
<surname>Quinlan</surname>, <given-names>C. L.</given-names>
</string-name>, <string-name>
<surname>Perevoshchikova</surname>, <given-names>I. V.</given-names>
</string-name>, <string-name>
<surname>Hey&#x2010;Mogensen</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Orr</surname>, <given-names>A. L.</given-names>
</string-name>, &amp; <string-name>
<surname>Brand</surname>, <given-names>M. D.</given-names>
</string-name> (<year>2013</year>). <article-title>Sites of reactive oxygen species generation by mitochondria oxidizing different substrates</article-title>. <source>Redox Biology</source>, <volume>1</volume>, <fpage>304</fpage>&#x2013;<lpage>312</lpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2013.04.005</pub-id>
<pub-id pub-id-type="pmid">24024165</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0022">
        <mixed-citation publication-type="journal" id="humu24453-cit-0022">
<string-name>
<surname>Riley</surname>, <given-names>L. G.</given-names>
</string-name>, <string-name>
<surname>Cowley</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Gayevskiy</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Minoche</surname>, <given-names>A. E.</given-names>
</string-name>, <string-name>
<surname>Puttick</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name>, <string-name>
<surname>Rius</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Compton</surname>, <given-names>A. G.</given-names>
</string-name>, <string-name>
<surname>Menezes</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Bhattacharya</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Coman</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ellaway</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>, <given-names>I. E.</given-names>
</string-name>, <string-name>
<surname>Adams</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Kava</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Sue</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Balasubramaniam</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Christodoulou</surname>, <given-names>J.</given-names>
</string-name> (<year>2020</year>, Jul). <article-title>The diagnostic utility of genome sequencing in a pediatric cohort with suspected mitochondrial disease</article-title>. <source>Genetics in Medicine</source>, <volume>22</volume>(<issue>7</issue>), <fpage>1254</fpage>&#x2013;<lpage>1261</lpage>. <pub-id pub-id-type="doi">10.1038/s41436-020-0793-6</pub-id>
<pub-id pub-id-type="pmid">32313153</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0023">
        <mixed-citation publication-type="journal" id="humu24453-cit-0023">
<string-name>
<surname>Salviati</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Sacconi</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Murer</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Zacchello</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Franceschini</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Laverda</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>Basso</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Quinzii</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Angelini</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Hirano</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Naini</surname>, <given-names>A. B.</given-names>
</string-name>, <string-name>
<surname>Navas</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>DiMauro</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Montini</surname>, <given-names>G.</given-names>
</string-name> (<year>2005</year>). <article-title>Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: A CoQ10&#x2010;responsive condition</article-title>. <source>Neurology</source>, <volume>65</volume>(<issue>4</issue>), <fpage>606</fpage>&#x2013;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000172859.55579.a7</pub-id>
<pub-id pub-id-type="pmid">16116126</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0024">
        <mixed-citation publication-type="journal" id="humu24453-cit-0024">
<string-name>
<surname>Santos&#x2010;Ocana</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Do</surname>, <given-names>T. Q.</given-names>
</string-name>, <string-name>
<surname>Padilla</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Navas</surname>, <given-names>P.</given-names>
</string-name>, &amp; <string-name>
<surname>Clarke</surname>, <given-names>C. F.</given-names>
</string-name> (<year>2002</year>, March 29). <article-title>Uptake of exogenous coenzyme Q and transport to mitochondria is required for bc1 complex stability in yeast coq mutants</article-title>. <source>Journal of Biological Chemistry</source>, <volume>277</volume>(<issue>13</issue>), <fpage>10973</fpage>&#x2013;<lpage>10981</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112222200</pub-id>
<pub-id pub-id-type="pmid">11788608</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0025">
        <mixed-citation publication-type="journal" id="humu24453-cit-0025">
<string-name>
<surname>Savojardo</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Martelli</surname>, <given-names>P. L.</given-names>
</string-name>, <string-name>
<surname>Fariselli</surname>, <given-names>P.</given-names>
</string-name>, &amp; <string-name>
<surname>Casadio</surname>, <given-names>R.</given-names>
</string-name> (<year>2015</year>, October 15). <article-title>TPpred3 detects and discriminates mitochondrial and chloroplastic targeting peptides in eukaryotic proteins</article-title>. <source>Bioinformatics</source>, <volume>31</volume>(<issue>20</issue>), <fpage>3269</fpage>&#x2013;<lpage>3275</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btv367</pub-id>
<pub-id pub-id-type="pmid">26079349</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0026">
        <mixed-citation publication-type="journal" id="humu24453-cit-0026">
<string-name>
<surname>Suarez&#x2010;Rivero</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Pastor&#x2010;Maldonado</surname>, <given-names>C. J.</given-names>
</string-name>, <string-name>
<surname>Povea&#x2010;Cabello</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Alvarez&#x2010;Cordoba</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Villalon&#x2010;Garcia</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Munuera&#x2010;Cabeza</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Suarez&#x2010;Carrillo</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Talaveron&#x2010;Rey</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Sanchez&#x2010;Alcazar</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2021</year>, February 4). <article-title>Coenzyme Q10 analogues: Benefits and challenges for therapeutics</article-title>. <source>Antioxidants (Basel)</source>, <volume>10</volume>(<issue>2</issue>), <elocation-id>236</elocation-id>. <pub-id pub-id-type="doi">10.3390/antiox10020236</pub-id>
<pub-id pub-id-type="pmid">33557229</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0027">
        <mixed-citation publication-type="journal" id="humu24453-cit-0027">
<string-name>
<surname>Takakubo</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Cartwright</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Hoogenraad</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name>, <string-name>
<surname>Collins</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Lithgow</surname>, <given-names>T.</given-names>
</string-name>, &amp; <string-name>
<surname>Dahl</surname>, <given-names>H. H.</given-names>
</string-name> (<year>1995</year>, October). <article-title>An amino acid substitution in the pyruvate dehydrogenase E1 alpha gene, affecting mitochondrial import of the precursor protein</article-title>. <source>American Journal of Human Genetics</source>, <volume>57</volume>(<issue>4</issue>), <fpage>772</fpage>&#x2013;<lpage>780</lpage>.<pub-id pub-id-type="pmid">7573035</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0028">
        <mixed-citation publication-type="journal" id="humu24453-cit-0028">
<string-name>
<surname>Torraco</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Stehling</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Stumpfig</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Rosser</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>De Rasmo</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Fiermonte</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Verrigni</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Rizza</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Vozza</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Di Nottia</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Diodato</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Martinelli</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Piemonte</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Dionisi&#x2010;Vici</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Bertini</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Lill</surname>, <given-names>R.</given-names>
</string-name>, &amp; <string-name>
<surname>Carrozzo</surname>, <given-names>R.</given-names>
</string-name> (<year>2018</year>, August 1). <article-title>ISCA1 mutation in a patient with infantile&#x2010;onset leukodystrophy causes defects in mitochondrial [4Fe&#x2010;4S] proteins</article-title>. <source>Human Molecular Genetics</source>, <volume>27</volume>(<issue>15</issue>), <fpage>2739</fpage>&#x2013;<lpage>2754</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddy183</pub-id>
<pub-id pub-id-type="pmid">29767723</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0029">
        <mixed-citation publication-type="journal" id="humu24453-cit-0029">
<string-name>
<surname>Wightman</surname>, <given-names>P. J.</given-names>
</string-name>, <string-name>
<surname>Santer</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Ribes</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Dougherty</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>McGill</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Thorburn</surname>, <given-names>D. R.</given-names>
</string-name>, &amp; <string-name>
<surname>FitzPatrick</surname>, <given-names>D. R.</given-names>
</string-name> (<year>2003</year>, October). <article-title>MLYCD mutation analysis: Evidence for protein mistargeting as a cause of MLYCD deficiency</article-title>. <source>Human Mutation</source>, <volume>22</volume>(<issue>4</issue>), <fpage>288</fpage>&#x2013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1002/humu.10264</pub-id>
<pub-id pub-id-type="pmid">12955715</pub-id>
</mixed-citation>
      </ref>
      <ref id="humu24453-bib-0030">
        <mixed-citation publication-type="journal" id="humu24453-cit-0030">
<string-name>
<surname>Witters</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Saada</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Honzik</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Tesarova</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Kleinle</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Horvath</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Morava</surname>, <given-names>E.</given-names>
</string-name> (<year>2018</year>, April). <article-title>Revisiting mitochondrial diagnostic criteria in the new era of genomics</article-title>. <source>Genetics in Medicine</source>, <volume>20</volume>(<issue>4</issue>), <fpage>444</fpage>&#x2013;<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1038/gim.2017.125</pub-id>
<pub-id pub-id-type="pmid">29261183</pub-id>
</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>